Abbott has received European clearance and is immediately launching its XIENCE Xpedition everolimus eluting stent in CE Mark compliant countries. The stent comes with a new delivery system and is particularly geared to use in difficult patients.
As part if its CE Mark indications is use of the device with a minimum of three month dual anti-platelet therapy (DAPT)., the shortest of any stent in Europe.
Long-term compliance to DAPT can be a challenge for patients and can lead to additional safety risks such as increased bleeding events. In addition, having a shorter DAPT duration after stent implantation may be beneficial in case a patient needs to interrupt or discontinue the medication prior to surgery or for other considerations.
XIENCE Xpedition is available in one of the broadest size matrices on the European market, with diameters ranging from 2.25 mm to 4 mm, including a unique 3.25 mm diameter, and lengths from 8 mm to 38 mm.